Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169).
Issues related to vaccine development and distribution.
Issues related to insulin pricing.
Issues related to FDA regulation of pharmaceuticals.
Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S.127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R.2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R.5378 - Lower Costs, More Transparency Act, and H.R.4366, Consolidated Appropriations Act.
Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program.
Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act.
S.3558, Biosecure.
Issues related to intellectual property and patent reform, including: S. 150, Affordable Prescriptions for Patients Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 113, Prescription Pricing for the People Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; and S. 148, Stop STALLING Act.
Issues related to waiving intellectual property protections for COVID-19 vaccines and thereaputics under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).
Issues related to the National Institute of Standards and Technology request for public comment on a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights.
Duration: January 19, 2019
to
present
General Issues: Pharmacy , Copyright/Patent/Trademark , Trade (Domestic & Foreign) , Medicare/Medicaid , Taxation/Internal Revenue Code , Immigration , Health Issues , Budget/Appropriations
Spending: about $920,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: House of Representatives, U.S. Senate, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), White House Office, Homeland Security - Dept of (DHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Hazen Marshall Policy Director, Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant, Senator Don Nickles
Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles
Monica Popp Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $40,000. The report was filed on April 19.
Original Filing: 301554464.xml
Lobbying Issues
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169).
Issues related to vaccine development and distribution.
Issues related to insulin pricing.
Issues related to FDA regulation of pharmaceuticals.
Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S.127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R.2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R.5378 - Lower Costs, More Transparency Act, and H.R.4366, Consolidated Appropriations Act.
Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program.
Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act.
S.3558, Biosecure.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to intellectual property and patent reform, including: S. 150, Affordable Prescriptions for Patients Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 113, Prescription Pricing for the People Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; and S. 148, Stop STALLING Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to waiving intellectual property protections for COVID-19 vaccines and thereaputics under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).
Issues related to the National Institute of Standards and Technology request for public comment on a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights.
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2023
In Q4, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $40,000. The report was filed on Jan. 15.
Original Filing: 301524672.xml
Lobbying Issues
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169).
Issues related to vaccine development and distribution.
Issues related to insulin pricing.
Issues related to FDA regulation of pharmaceuticals.
Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act.
Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program.
Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to intellectual property and patent reform, including: S. 150, Affordable Prescriptions for Patients Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 113, Prescription Pricing for the People Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; and S. 148, Stop STALLING Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to waiving intellectual property protections for COVID-19 vaccines and thereaputics under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).
Issues related to the National Institute of Standards and Technology request for public comment on a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights.
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2023
In Q3, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $40,000. The report was filed on Oct. 19, 2023.
Original Filing: 301506010.xml
Lobbying Issues
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169).
Issues related to vaccine development and distribution.
Issues related to insulin pricing.
Issues related to FDA regulation of pharmaceuticals.
Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act.
Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program.
Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to intellectual property and patent reform, including: S. 150, Affordable Prescriptions for Patients Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 113, Prescription Pricing for the People Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; and S. 148, Stop STALLING Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to waiving intellectual property protections for COVID-19 vaccines under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2023
In Q2, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $40,000. The report was filed on July 14, 2023.
Original Filing: 301476535.xml
Lobbying Issues
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169).
Issues related to vaccine development and distribution.
Issues related to insulin pricing.
Issues related to FDA regulation of pharmaceuticals.
Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, and H.R. 2679, the PBM Accountability Act.
Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program.
Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to intellectual property and patent reform, including: S. 150, Affordable Prescriptions for Patients Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 113, Prescription Pricing for the People Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; and S. 148, Stop STALLING Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to waiving intellectual property protections for COVID-19 vaccines under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2023
In Q1, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $40,000. The report was filed on April 19, 2023.
Original Filing: 301459495.xml
Lobbying Issues
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169).
Issues related to vaccine development and distribution.
Issues related to 340B.
Issues related to insulin pricing.
Issues related to FDA regulation of pharmaceuticals.
Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to intellectual property and patent reform, including: S. 150, Affordable Prescriptions for Patients Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 113, Prescription Pricing for the People Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; and S. 148, Stop STALLING Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to waiving intellectual property protections for COVID-19 vaccines under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2022
In Q4, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $40,000. The report was filed on Jan. 14, 2023.
Original Filing: 301427709.xml
Lobbying Issues
Issues related to prescription drug value, including implementation of H.R. 5376, the Inflation Reduction Act.
Issues related to vaccine development and distribution.
Issues related to supply chains, 340B, and the COVID-19 pandemic.
Issues related to insulin, including H.R.6833, Affordable Insulin Now Act.
Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R. 2617, Consolidated Appropriations Act.
H.R.3932, the Pasteur Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to intellectual property and patent reform, including S.1435, the Affordable Prescriptions for Patients Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to waiving intellectual property protections for COVID-19 vaccines under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2022
In Q3, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $40,000. The report was filed on Oct. 21, 2022.
Original Filing: 301420221.xml
Lobbying Issues
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Inflation Reduction Act.
Issues related to vaccine development and distribution.
Issues related to supply chains, 340B, and the COVID-19 pandemic.
Issues related to insulin, including H.R.6833, Affordable Insulin Now Act.
Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R. 6833, making continuing appropriations for fiscal year 2023.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to intellectual property and patent reform, including S.1435, the Affordable Prescriptions for Patients Act, H.R.4521/S.1260, the United States Innovation and Competition Act, and H.R. 4346, the CHIPS and Science Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to waiving intellectual property protections for COVID-19 vaccines under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2022
In Q2, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $40,000. The report was filed on July 17, 2022.
Original Filing: 301381936.xml
Lobbying Issues
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S. 2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14.
Issues related to vaccine development and distribution.
Issues related to supply chains, 340B, and the COVID-19 pandemic.
Issues related to insulin, including H.R.6833, Affordable Insulin Now Act.
Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to intellectual property and patent reform, including S.1435, the Affordable Prescriptions for Patients Act; and H.R.4521/S.1260, the United States Innovation and Competition Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to waiving intellectual property protections for COVID-19 vaccines under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to the False Claims Act, including S.2428 - False Claims Amendments Act of 2021.
1st Quarter, 2022
In Q1, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $40,000. The report was filed on April 18, 2022.
Original Filing: 301359874.xml
Lobbying Issues
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S. 2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res.14.
Issues related to vaccine development and distribution.
Issues related to supply chains, 340B, and the COVID-19 pandemic.
H.R.2471, Consolidated Appropriations Act, issues related to 340B.
Issues related to insulin, including H.R.6833, Affordable Insulin Now Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to intellectual property and patent reform, including S.1435, the Affordable Prescriptions for Patients Act; and H.R.4521/S.1260, the United States Innovation and Competition Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to waiving intellectual property protections for COVID-19 vaccines under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to the False Claims Act, including S.2428 - False Claims Amendments Act of 2021.
4th Quarter, 2021
In Q4, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $40,000. The report was filed on Jan. 13, 2022.
Original Filing: 301322390.xml
Lobbying Issues
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S. 2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14.
Issues related to vaccine development and distribution.
Issues related to supply chains, 340B, and the COVID-19 pandemic.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to intellectual property and patent reform, including S.1435, the Affordable Prescriptions for Patients Act; and S.1260, the United States Innovation and Competition Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to waiving intellectual property protections for COVID-19 vaccines under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to the False Claims Act, including S.2428 - False Claims Amendments Act of 2021.
Lobbying Issues
Issues related to the taxation of vaccines, including H.R.3656/S.3087 - Vaccine Access Improvement Act of 2021.
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2021
In Q3, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $40,000. The report was filed on Oct. 16, 2021.
Original Filing: 301300320.xml
Lobbying Issues
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S. 2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14.
Issues related to vaccine development and distribution.
Issues related to supply chains, 340B, and the COVID-19 pandemic.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to intellectual property and patent reform, including S.1435, the Affordable Prescriptions for Patients Act; and S.1260, the United States Innovation and Competition Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to waiving intellectual property protections for COVID-19 vaccines under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to the False Claims Act, including amendments to H.R.3684 - Infrastructure Investment and Jobs Act.
2nd Quarter, 2021
In Q2, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $40,000. The report was filed on July 13, 2021.
Original Filing: 301275754.xml
Lobbying Issues
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act.
Issues related to vaccine development and distribution.
Issues related to supply chains, 340B, and the COVID-19 pandemic.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to intellectual property and patent reform, including S.1435, the Affordable Prescriptions for Patients Act; and S.1260, the United States Innovation and Competition Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to waiving intellectual property protections for COVID-19 vaccines under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement).
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2021
In Q1, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $40,000. The report was filed on April 16, 2021.
Original Filing: 301254391.xml
Lobbying Issues
Issues related to prescription drug value, supply chains, 340B, and the COVID-19 pandemic, including:
*S.Con.Res. 5, fiscal year 2021 budget resolution.
*H.R.1319: American Rescue Plan Act of 2021.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to protection of intellectual property.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2020
In Q4, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301239680.xml
Lobbying Issues
Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019, and H.R.19/S.3129: Lower Costs, More Cures Act of 2019.
Issues related to supply chain and Buy America requirements.
Biosimilars.
Importation of prescription drugs.
340B issues.
FDA regulatory issues, including the International Pricing Index.
Issues related to the COVID-19 pandemic, including H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, and S.4775, Delivering Immediate Relief to America's Families, Schools and Small Businesses Act. H.R.133 [116th]: Consolidated Appropriations Act, 2021.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.1416: Affordable Prescriptions for Patients Act of 2019, issues related to patents and protection of intellectual property.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to employee VISAs.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on Oct. 19, 2020.
Original Filing: 301215020.xml
Lobbying Issues
Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019, and H.R.19/S.3129: Lower Costs, More Cures Act of 2019.
Issues related to supply chain and Buy America requirements.
Biosimilars.
Importation of prescription drugs.
340B issues.
FDA regulatory issues, including the International Pricing Index.
Issues related to the COVID-19 pandemic, including H.R.6800: Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, and S.4775, Delivering Immediate Relief to America's Families, Schools and Small Businesses Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patents and protection of intellectual property issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to employee VISAs.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301201149.xml
Lobbying Issues
Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3/: Lower Drug Costs Now Act of 2019, and H.R.19/S.3129: Lower Costs, More Cures Act of 2019.
Issues related to supply chain and Buy America requirements.
Biosimilars.
Importation of prescription drugs.
340B issues.
FDA regulatory issues, including the International Pricing Index.
Issues related to the COVID-19 pandemic.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patents and protection of intellectual property issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to employee VISAs.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on April 13, 2020.
Original Filing: 301165871.xml
Lobbying Issues
Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3/: Lower Drug Costs Now Act of 2019, and H.R.19/S.3129: Lower Costs, More Cures Act of 2019.
Biosimilars.
Importation of prescription drugs.
340B issues.
FDA regulatory issues, including the International Pricing Index.
Issues related to the COVID-19 pandemic.
H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020.
H.R.6201: Families First Coronavirus Response Act.
H.R.748: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patents and protection of intellectual property issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2019
In Q4, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on Jan. 21, 2020.
Original Filing: 301128214.xml
Lobbying Issues
Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019, and H.R.19: Lower Costs, More Cures Act of 2019.
Biosimilars.
Importation of prescription drugs.
340B issues.
FDA regulatory issues, including the International Pricing Index.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patents and protection of intellectual property issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2019
In Q3, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on Oct. 16, 2019.
Original Filing: 301066237.xml
Lobbying Issues
Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019.
Biosimilars.
Importation of prescription drugs.
340B issues.
FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patents and protection of intellectual property issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2019
In Q2, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on July 10, 2019.
Original Filing: 301044312.xml
Lobbying Issues
Prescription drug value issues.
Biosimilars.
Importation of prescription drugs.
340B issues.
FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patents and protection of intellectual property issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2019
In Q1, MARSHALL & POPP, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on April 22, 2019.
Original Filing: 301036886.xml
Lobbying Issues
Prescription drug value issues.
Biosimilars.
Importation of prescription drugs.
340B issues.
FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2019
MARSHALL & POPP, LLC filed a lobbying registration on March 1, 2019 to represent Pharmaceutical Research and Manufacturers of America, effective Jan. 19, 2019.
Original Filing: 301020945.xml
Issue(s) they said they’d lobby about: Healthcare policy issues as they relate to the pharmaceutical industry including prescription drug value issues, FDA and biosimilars. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...